Zacks: Analysts Anticipate Reata Pharmaceuticals Inc (RETA) to Post -$1.12 EPS

Share on StockTwits

Equities analysts expect Reata Pharmaceuticals Inc (NASDAQ:RETA) to report earnings per share (EPS) of ($1.12) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Reata Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.14) and the highest estimate coming in at ($1.10). Reata Pharmaceuticals reported earnings per share of ($1.04) in the same quarter last year, which would indicate a negative year-over-year growth rate of 7.7%. The business is scheduled to announce its next quarterly earnings report on Wednesday, August 14th.

According to Zacks, analysts expect that Reata Pharmaceuticals will report full year earnings of ($4.62) per share for the current financial year, with EPS estimates ranging from ($4.93) to ($4.18). For the next fiscal year, analysts forecast that the company will post earnings of ($3.57) per share, with EPS estimates ranging from ($4.80) to ($1.20). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Reata Pharmaceuticals.

Reata Pharmaceuticals (NASDAQ:RETA) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($0.01). The business had revenue of $7.77 million during the quarter, compared to analysts’ expectations of $7.92 million.

Several research analysts have issued reports on the company. Zacks Investment Research cut Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday. BidaskClub upgraded Reata Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, May 7th. Cantor Fitzgerald set a $100.00 price objective on Reata Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, February 20th. Finally, ValuEngine upgraded Reata Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $100.33.

NASDAQ:RETA traded down $0.51 during trading hours on Thursday, hitting $92.03. The company’s stock had a trading volume of 232,500 shares, compared to its average volume of 227,631. The stock has a market capitalization of $2.79 billion, a price-to-earnings ratio of -32.07 and a beta of 2.91. The company has a debt-to-equity ratio of 5.23, a quick ratio of 6.12 and a current ratio of 5.19. Reata Pharmaceuticals has a 52-week low of $30.76 and a 52-week high of $104.53.

In related news, insider Elaine Castellanos sold 3,588 shares of Reata Pharmaceuticals stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $102.00, for a total transaction of $365,976.00. Following the completion of the sale, the insider now owns 5,726 shares in the company, valued at approximately $584,052. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Keith Wayne Ward sold 15,183 shares of Reata Pharmaceuticals stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $91.00, for a total value of $1,381,653.00. Following the sale, the insider now owns 23,803 shares of the company’s stock, valued at approximately $2,166,073. The disclosure for this sale can be found here. In the last quarter, insiders have sold 44,227 shares of company stock valued at $4,093,386. 31.69% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of the stock. TD Asset Management Inc. increased its position in Reata Pharmaceuticals by 1.3% during the 1st quarter. TD Asset Management Inc. now owns 15,813 shares of the company’s stock worth $1,352,000 after purchasing an additional 200 shares in the last quarter. State Board of Administration of Florida Retirement System increased its position in Reata Pharmaceuticals by 3.8% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 7,902 shares of the company’s stock worth $675,000 after purchasing an additional 290 shares in the last quarter. Legal & General Group Plc increased its position in Reata Pharmaceuticals by 11.5% during the 4th quarter. Legal & General Group Plc now owns 3,414 shares of the company’s stock worth $192,000 after purchasing an additional 352 shares in the last quarter. Eagle Global Advisors LLC increased its position in Reata Pharmaceuticals by 6.7% during the 1st quarter. Eagle Global Advisors LLC now owns 6,400 shares of the company’s stock worth $547,000 after purchasing an additional 400 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Reata Pharmaceuticals by 100.2% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 991 shares of the company’s stock worth $85,000 after purchasing an additional 496 shares in the last quarter. Hedge funds and other institutional investors own 53.42% of the company’s stock.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.

See Also: Federal Reserve

Get a free copy of the Zacks research report on Reata Pharmaceuticals (RETA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

State of Wisconsin Investment Board Buys 5,300 Shares of Banner Co.
State of Wisconsin Investment Board Buys 5,300 Shares of Banner Co.
Principal Financial Group Inc. Has $23.51 Million Holdings in Diamondback Energy Inc
Principal Financial Group Inc. Has $23.51 Million Holdings in Diamondback Energy Inc
Camden Property Trust  Holdings Trimmed by Westwood Holdings Group Inc.
Camden Property Trust Holdings Trimmed by Westwood Holdings Group Inc.
Neuburgh Advisers LLC Cuts Stake in Apache Co.
Neuburgh Advisers LLC Cuts Stake in Apache Co.
Principal Financial Group Inc. Has $24.44 Million Stake in Versum Materials Inc
Principal Financial Group Inc. Has $24.44 Million Stake in Versum Materials Inc
DPRating Trading 4.1% Higher  Over Last Week
DPRating Trading 4.1% Higher Over Last Week


© 2006-2019 Ticker Report